| Today, Mon, Nov 9, 2009 | | • | Ask Your Doctor If This Ad Is Right for You
at BusinessWeek (Mon 5:01pm)
| | • | A Big Upgrade for Gilead Sciences
at Motley Fool (Mon 1:31pm)
| | • | FDA delays review of GlaxoSmithKline pain drug
at bizjournals.com (Mon 11:05am)
| | • | Xoma Waffles on Timing of Drug Partnership: BioBuzz
at TheStreet.com (Mon 10:23am)
| | • | FDA extends review of XenoPort-Glaxo pain drug
AP (Mon 8:39am)
| | • | 5-Star Stocks Poised to Pop: Gilead Sciences
at Motley Fool (Mon 8:13am)
| | • | Ariad Upgraded, Xenoport Drug Delayed: BioBuzz
at TheStreet.com (Mon 7:51am)
| | • | AstraZeneca lifted to buy, Roche cut to hold: RBS
at MarketWatch (Mon 3:53am)
| | • | AstraZeneca downgraded to underweight at JP Morgan
at MarketWatch (Mon 3:21am)
| | Sat, Nov 7, 2009 | | • | Santarus Reports Strong Quarter
Zacks.com (Sat, Nov 7)
| | Fri, Nov 6, 2009 | | • | GlaxoSmithKline and XenoPort Announce Extension of GSK1838262 (XP13512) FDA Review Date to February 9, 2010
Business Wire (Fri, Nov 6)
| | • | No Product Revenues, Plenty of Risk: Buy Exelixis?
at CNBC (Fri, Nov 6)
| | • | The Downside of Dollar-Cost Averaging
at Motley Fool (Fri, Nov 6)
| | • | Oculus, Bianco and Cel-Sci Oh My!: BioBuzz
at TheStreet.com (Fri, Nov 6)
| | • | Biosimilars, Biologics, Biotech And Specialty Pharmaceuticals: Piper Jaffray Picks The Stocks And Sectors With Highest Potential Returns For Investors
Wall Street Transcript (Fri, Nov 6)
| | • | BioCryst Competition for IV Flu Drug: BioBuzz
at TheStreet.com (Fri, Nov 6)
| | • | The Top 4 Healthcare Dividend Stocks: Covered Call Trades
at Seeking Alpha (Fri, Nov 6)
| | Thu, Nov 5, 2009 | | • | Rail Worker Killed as Strike Snarls Philadelphia
at The Wall Street Journal Online (Thu, Nov 5)
| | • | Slow Down There, Merck
at Motley Fool (Thu, Nov 5)
| | • | Placing Bets On Human Genome's Benlysta
Indie Research (Thu, Nov 5)
|
Add GSK News to My Yahoo!:
 
| |
|
2.03% Nasdaq 
Headlines
